Paul Alloway - Mar 25, 2024 Form 4 Insider Report for Homology Medicines, Inc. (FIXX)

Role
President and Chief Operating Officer
Signature
/s/ Paul Alloway
Stock symbol
FIXX
Transactions as of
Mar 25, 2024
Transactions value $
$0
Form type
4
Date filed
3/27/2024, 04:15 PM
Previous filing
Jan 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FIXX Common Stock Options Exercise +23.5K +83.93% 51.6K Mar 25, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FIXX Restricted Stock Units Options Exercise $0 -5.44K -100% $0.00* 0 Mar 25, 2024 Common Stock 5.44K Direct F1, F2
transaction FIXX Restricted Stock Units Options Exercise $0 -18.1K -100% $0.00* 0 Mar 25, 2024 Common Stock 18.1K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Paul Alloway is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
F2 The vesting of these RSUs has been accelerated such that the RSUs vested in full on March 25, 2024, immediately prior to the Effective Time as defined in that certain Agreement and Plan of Merger by and among the Issuer, Kenobi Merger Sub, Inc. and Q32 Bio Inc. dated November 16, 2023.

Remarks:

President and Chief Operating Officer